334 related articles for article (PubMed ID: 29604930)
1. Oncogenic Signaling Pathways and Pathway-Based Therapeutic Biomarkers in Lymphoid Malignancies.
Sun R; Wang J; Young KH
Crit Rev Oncog; 2017; 22(5-6):527-557. PubMed ID: 29604930
[TBL] [Abstract][Full Text] [Related]
2. Critically dysregulated signaling pathways and clinical utility of the pathway biomarkers in lymphoid malignancies.
Sun RF; Yu QQ; Young KH
Chronic Dis Transl Med; 2018 Mar; 4(1):29-44. PubMed ID: 29756121
[TBL] [Abstract][Full Text] [Related]
3. Precision therapy for lymphoma--current state and future directions.
Intlekofer AM; Younes A
Nat Rev Clin Oncol; 2014 Oct; 11(10):585-96. PubMed ID: 25135367
[TBL] [Abstract][Full Text] [Related]
4. Advances in targeted therapy for malignant lymphoma.
Wang L; Qin W; Huo YJ; Li X; Shi Q; Rasko JEJ; Janin A; Zhao WL
Signal Transduct Target Ther; 2020 Mar; 5(1):15. PubMed ID: 32296035
[TBL] [Abstract][Full Text] [Related]
5. Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents.
Inamdar AA; Goy A; Ayoub NM; Attia C; Oton L; Taruvai V; Costales M; Lin YT; Pecora A; Suh KS
Oncotarget; 2016 Jul; 7(30):48692-48731. PubMed ID: 27119356
[TBL] [Abstract][Full Text] [Related]
6. Double hit lymphoma: from biology to therapeutic implications.
Burotto M; Berkovits A; Dunleavy K
Expert Rev Hematol; 2016 Jul; 9(7):669-78. PubMed ID: 27166590
[TBL] [Abstract][Full Text] [Related]
7. Molecular heterogeneity in diffuse large B-cell lymphoma and its implications in clinical diagnosis and treatment.
Guo L; Lin P; Xiong H; Tu S; Chen G
Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):85-96. PubMed ID: 29337112
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic targeting in lymphoma.
Booth S; Collins G
Br J Haematol; 2021 Jan; 192(1):50-61. PubMed ID: 32609383
[TBL] [Abstract][Full Text] [Related]
9. NF-κB signaling pathway and its potential as a target for therapy in lymphoid neoplasms.
Yu L; Li L; Medeiros LJ; Young KH
Blood Rev; 2017 Mar; 31(2):77-92. PubMed ID: 27773462
[TBL] [Abstract][Full Text] [Related]
10. Role of Bruton's tyrosine kinase in B cells and malignancies.
Pal Singh S; Dammeijer F; Hendriks RW
Mol Cancer; 2018 Feb; 17(1):57. PubMed ID: 29455639
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic target discovery and drug development in cancer stem cells for leukemia and lymphoma: from bench to the clinic.
Laranjeira AB; Yang SX
Expert Opin Drug Discov; 2016 Nov; 11(11):1071-1080. PubMed ID: 27626707
[TBL] [Abstract][Full Text] [Related]
12. Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review.
Camicia R; Winkler HC; Hassa PO
Mol Cancer; 2015 Dec; 14():207. PubMed ID: 26654227
[TBL] [Abstract][Full Text] [Related]
13. Targeting oncogenic and epigenetic survival pathways in lymphoma.
Leslie LA; Younes A
Leuk Lymphoma; 2013 Nov; 54(11):2365-76. PubMed ID: 23442067
[TBL] [Abstract][Full Text] [Related]
14. Targeting indolent non-Hodgkin lymphoma.
Leslie LA; Skarbnik AP; Bejot C; Stives S; Feldman TA; Goy AH
Expert Rev Hematol; 2017 Apr; 10(4):299-313. PubMed ID: 28277849
[TBL] [Abstract][Full Text] [Related]
15. New targeted therapies for malignant lymphoma based on molecular heterogeneity.
Horn H; Staiger AM; Ott G
Expert Rev Hematol; 2017 Jan; 10(1):39-51. PubMed ID: 27918211
[TBL] [Abstract][Full Text] [Related]
16. Overview: A New Era of Cancer Genomics in Lymphoid Malignancies.
Iida S
Oncology; 2015; 89 Suppl 1():4-6. PubMed ID: 26551834
[TBL] [Abstract][Full Text] [Related]
17. Genomic alterations underlying immune privilege in malignant lymphomas.
Mottok A; Steidl C
Curr Opin Hematol; 2015 Jul; 22(4):343-54. PubMed ID: 26049756
[TBL] [Abstract][Full Text] [Related]
18. Current status and progress of lymphoma management in China.
Shi Y
Int J Hematol; 2018 Apr; 107(4):405-412. PubMed ID: 29388166
[TBL] [Abstract][Full Text] [Related]
19. Colorectal cancer heterogeneity and targeted therapy: Clinical implications, challenges and solutions for treatment resistance.
Zhai Z; Yu X; Yang B; Zhang Y; Zhang L; Li X; Sun H
Semin Cell Dev Biol; 2017 Apr; 64():107-115. PubMed ID: 27578007
[TBL] [Abstract][Full Text] [Related]
20. Rational combination therapies targeting survival signaling in aggressive B-cell leukemia/lymphoma.
Waibel M; Gregory G; Shortt J; Johnstone RW
Curr Opin Hematol; 2014 Jul; 21(4):297-308. PubMed ID: 24811162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
